2024 annual financial data
Sarepta Therapeutics 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was -10.82%.
Operating income was 218,081,000 USD and net income was 235,239,000 USD.
Operating cash flow was -205,787,000 USD.
Get free Sarepta Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,901,979,000 USD
- Operating income
- 218,081,000 USD
- Net income
- 235,239,000 USD
- Operating cash flow
- -205,787,000 USD